Skip to main content
Premium Trial:

Request an Annual Quote

Userspace to Evaluate IPFlex Processor for Proteomics Research Project

NEW YORK, April 25 (GenomeWeb News) - Userspace has begun an evaluation of IPFlex's DAPDNA-2, a reconfigurable processor, for use in a National Institutes of Health-sponsored proteomics research project, the companies said today.

 

In October, Userspace received a two-year NIH grant worth $394,000 to research and develop instrument routers for protein processing, the companies said. Real-time tagging and data modeling of mass spectrometry data is a central theme of this project, they added.

 

"With protein characterization now one of the cornerstones of systems biology, real-time mass spectrometry will spearhead the understanding of disease processes. This means tagging and searching of mass spectral data in real-time," Sanjaya Joshi, co-founder and CTO of Userspace, said in a statement. "The IPFlex DAPDNA platform would be evaluated as a flow-processor for this standardization."

 

Tokyo-based IPFlex first launched the processor in Japan last year, and began marketing it in the US in January. Userspace is the first US customer.

 

Specific terms of the companies arrangement were not disclosed.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.